Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Stomach Neoplasms 30Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 15Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Sarcoma 13Ovarian Neoplasms 12Breast Neoplasms 12Triple Negative Breast Neoplasms 9Nasopharyngeal Carcinoma 9Esophageal Squamous Cell Carcinoma 9Cholangiocarcinoma 9Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Osteosarcoma 6Lung Neoplasms 6Pancreatic Neoplasms 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Neoplasms 4Melanoma 4Solid Tumor 3Recurrence 3Neoplasm Metastasis 3Liver Neoplasms 3Glioma 3Gastric Adenocarcinoma 3Carcinoma, Adenoid Cystic 3

Interventions

pegaspargase 15fludarabine phosphate 15Mycophenolic Acid 14Busulfan 14Tacrolimus 13Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 12Etoposide 12Dexamethasone 12Whole-Body Irradiation 11Methotrexate 10Gemcitabine 10Antilymphocyte Serum 9Radiotherapy 7Cyclosporine 7spartalizumab 6Oxaliplatin 5Asparaginase 5Transplantation 4Rituximab 4Melphalan 4Flow Cytometry 4tislelizumab 3thymoglobulin 3sintilimab 3selinexor 3pembrolizumab 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Extranodal NK-T-Cell × apatinib × Clear all
NCT03701022 2018-10-09

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Peking University

Phase 2 Unknown
61 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡